Novartis AG/Incyte Corporation Drug Said to Ease Blood-Cancer Symptoms

September 16, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

NEW YORK, Sept 15 (Reuters) - An experimental Novartis AG (NOVN.VX) medicine in an early-stage trial provided marked relief of symptoms to patients with a rare life-threatening blood cancer called myelofibrosis, the drugmaker said on Wednesday.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase I

Incyte Novartis